Introduction
Coagulation cascade activation, marked by thrombin generation, hepatic fibrin deposition, and platelet activation is a conspicuous feature of cholestatic liver disease in humans [1] [2] [3] , which is recapitulated in experimental settings of chronic liver injury [2, 4] . Experimental evidence supports a role for protease activated receptors (PARs), including the thrombin receptor PAR-1, in promoting liver fibrosis [5, 6] . PAR-1 deficiency reduced hepatic collagen deposition in models of carbon tetrachloride, bile duct ligation (BDL) and alphanaphthylisothiocyanate (ANIT)-induced liver fibrosis [2, 4, 7, 8] , an observation likely connected to PAR-1 expression by macrophages and/or hepatic stellate cells [4, 8, 9] . Unlike humans, PAR-1 is not expressed by mouse platelets, and thrombin-mediated platelet activation is intact in PAR-1-deficient mice [10] . A complex of PAR-3 and PAR-4 contributes to thrombin-mediated platelet activation in mice [11, 12] . Thus, while PAR-1 −/− mice have provided compelling evidence of profibrogenic effects of thrombin, these cannot be attributed to platelet activation. Indeed, the mechanisms coupling thrombin activity to platelet activation in models of liver fibrosis have not been fully explored. It is conceivable that thrombin, through activation of PAR-1 (in humans) or PAR-3/4 (in mice), is central to platelet activation in liver disease. Thrombin is a very potent activator of platelets, causing degranulation and release of stored mediators, including serotonin [13] . Platelet activation by diverse mediators, including thrombin, alters the conformation of integrin α IIb β 3 , revealing a high affinity binding site for fibrin(ogen) [14] . Fibrin(ogen) engagement of activated α IIb β 3 integrin can further modify platelet activation, being critical for platelet aggregation and clot retraction [14, 15] . Demonstrating the importance of this interaction, mice expressing a mutant fibrin(ogen) incapable of binding activated α IIb β 3 integrin have defective platelet aggregation, despite retention of other fibrin(ogen)-dependent hemostatic functions [15] . However, the role of this functional interaction between platelets and fibrin(ogen) in chronic liver injury has not yet been defined.
The contribution of platelets in experimental settings of liver damage and fibrosis appears to be context-dependent. Studies suggest that platelets can either promote or reduce liver injury and fibrosis. The specific role of platelets depends on the etiology of the liver disease or nature of the hepatic injury [16] . Moreover, experimental variables including the degree and duration of platelet deficiency or inhibition also impacts the outcome with respect to liver injury and fibrosis [17, 18] . For example, platelets exacerbate acute cholestatic liver injury in multiple models [19] [20] [21] , whereas long-term thrombocytopenia or serotonin deficiency exacerbates liver fibrosis [17, 22] . Coagulation-mediated platelet activation, through both thrombin-and fibrin(ogen)-mediated mechanisms, is central to normal hemostasis [23] . However, the impact of these platelet activation pathways on chronic cholestatic liver injury has not yet been specifically evaluated.
In the present study, we sought to identify key mechanisms that link platelet function to liver injury and fibrosis in an experimental setting of chronic bile duct injury. Utilizing PAR-4 deficient mice (PAR-4 −/− ) and mice expressing a mutant form of fibrin(ogen) lacking the binding motif for integrin α IIb β 3 (Fibγ Δ5 ) [15, 24] , we determined the role of thrombinmediated platelet activation and fibrin(ogen)-platelet interactions through the integrin α IIb β 3 in chronic biliary injury and fibrosis.
Materials and Methods
Mice PAR-4 −/− mice, Fibγ Δ5 mice, and wild-type mice backcrossed at least 8 generations on the same C57Bl/6J background, were maintained by homozygous breeding [15, 24] . Agematched male mice between the ages of 8-14 weeks were used for these studies. Mice were housed at an ambient temperature of approximately 22°C with alternating 12 hour light/12 hour dark cycles and provided purified water and rodent chow ad libitum prior to study initiation. Mice were maintained in Association for Assessment and Accreditation of Laboratory Animal Care International-accredited facilities at Michigan State University or Cincinnati Children's Hospital Medical Center. All animal procedures were approved by Michigan State University or Cincinnati Children's Hospital Medical Center Institutional Animal Care and Use Committees.
ANIT diet model
Custom diets were prepared by Dyets, Inc. (Bethlehem, PA). The ANIT diet was an AIN-93M diet containing 0.025% ANIT (Sigma-Aldrich, St. Louis, MO). The control diet was AIN-93M diet. Groups of mice were fed each diet for a total of 4 weeks, ad libitum. Mice fed ANIT diet are referred to as ANIT-treated mice. Mice were anesthetized with isoflurane, and blood was collected from the caudal vena cava into sodium citrate (final, 0.38%) or an empty syringe for the collection of plasma and serum, respectively. The liver was removed and washed with saline. The left medial lobe of the liver was affixed to cork with optimal cutting temperature compound (VWR Scientific, Radnor, PA) and frozen for 3 minutes in liquid nitrogen-chilled isopentane. Sections of the left lateral lobe were fixed in neutral-buffered formalin for 48 hours prior to routine processing. The remaining liver was cut into approximately 100 mg sections and flash-frozen in liquid nitrogen.
Histopathology and clinical chemistry
For analysis of liver histopathology by light microscopy, formalin-fixed liver sections were cut at 5 microns and stained with hematoxylin and eosin (H&E) and sirius red by the Michigan State University Investigative Histopathology Laboratory. At least 2 sections of liver from the left lateral lobe of each animal were qualitatively evaluated in their entirety by a Board-certified veterinary pathologist (K.J.W.). Quantitative measures of necrosis (i.e., lesion frequency and size) in H&E-stained sections were performed in a masked fashion using ImageJ. For quantification of Sirius red staining (collagen deposits), images of Siriusred stained liver sections were captured using a Virtual Slide System VS110 (Olympus, Hicksville, NY) with a 20X objective. Random images were derived from the digitized slides approximating at least 100 mm 2 tissue for each liver. The area of positive sirius red staining in each image was determined in an unbiased fashion using a batch macro and the color deconvolution tool in ImageJ. Total bile acids in serum were determined using a colorimetric assay (Bio-Quant, San Diego, CA) and serum activities of alanine aminotransferase (ALT) and alkaline phosphatase (ALP) were determined using commercial reagents (Thermo Scientific, Waltham, MA; Pointe Scientific, Canton, MI). Plasma thrombin-antithrombin (TAT) and serotonin levels were determined using commercial enzyme-linked immunosorbent assay kits (Siemens Healthcare Diagnostics, Deerfield, IL; Eagle Biosciences, Nashua, NH). Serum cytokine levels (IL-6, IL-4, KC/Gro, TNFα) were determined using the Meso Scale V-PLEX Proinflammatory Panel Kit and a Sector 600 Imager (Meso Scale Discovery, Rockville, MD).
Immunohistochemistry and immunofluorescence
α-smooth muscle actin (α-SMA) immunohistochemistry was performed as described previously [25] , with slight modification. Briefly, sections were de-paraffinized in xylene and subjected to heat-mediated antigen retrieval in citrate buffer (10 mM, pH 6). Sections were incubated with primary rabbit-anti α-SMA antibody (1:750) (Abcam, Cambridge, MA). Fibrin(ogen) immunohistochemistry was performed on de-paraffinized formalin-fixed sections after antigen retrieval with proteinase K, using a rabbit anti-human fibrin(ogen) antibody (1:600) (Dako North America, Carpinteria, CA). Each primary antibody was detected utilizing a biotinylated goat anti-rabbit antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) and Vectastain Elite ABC kit and ImmPACT DAB substrate (Vector Laboratories, Burlingame, CA). Immunofluorescent staining of type 1 collagen, cytokeratin-19 (CK19) and integrin α IIb /CD41 (platelet) were performed as described [2, 20, 26] . Prolong Gold (DAPI-containing) Antifade reagent (Life Technologies) was applied to the tissues prior to cover slipping. Fluorescent staining in liver sections was visualized using an Olympus DP70 microscope (Olympus, Lake Success, NY) and merged (as appropriate) using Olympus DP Manager software. Type 1 collagen and CK19 staining was quantified using Scion Image (Scion Corporation, Frederick, MD) as described previously [2] , utilizing approximately 10 low-power images (100X) for each tissue. The percentage of pixels containing positive signal (i.e., collagen staining) was expressed as a fold change relative to wild-type mice fed control diet. Neutrophil and CD3 staining on paraffin-embedded, formalin-fixed sections was accomplished using monoclonal rat anti-mouse allotypic neutrophil marker (PMN 7/4) and rabbit polyclonal anti-CD3 (Abcam), respectively, and was performed by the Michigan State University Investigative Histopathology Laboratory. Quantification of α-SMA and CD3 positive staining was performed using digitized slides and ImageJ as described for Sirius red staining (above).
RNA isolation, cDNA synthesis, and real-time PCR
Total RNA was isolated from approximately 15 mg of snap-frozen liver using TRI Reagent (Molecular Research Center, Cincinnati, OH). 1 μg of total RNA was utilized for the synthesis of cDNA, accomplished using a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) and a C1000 Thermal Cycler (Bio-Rad Laboratories, Hercules, CA). Hepatic levels of mRNAs encoding the profibrogenic genes type 1 collagen (COL1A1), integrin β6 (ITGB6), transforming growth factor-1 (TGFβ1) and -2 (TGFβ2) and tissue inhibitor of metalloproteinase1 (TIMP-1) were determined using SYBR Green PCR, iTaq (Bio-Rad), and a CFX Connect thermal cycler (Bio-Rad). Primers were purchased from IDT (Coralville, IA). The expression of each gene was adjusted to the geometric mean Ct of two individual housekeeper genes, HPRT and 18S RNA, as described [27] , and the relative levels of each gene were evaluated using the ΔΔCt method. Sequences for primers used are available in supplemental data.
Platelet isolation and stimulation
Approximately 0.5 mL whole blood was collected from the caudal vena cava into acid citrate dextrose (ACD) and added to an equivalent volume of pipes saline glucose (PSG). Platelet-rich plasma was mixed with PSG containing 1 μM PGE 1 and 0.02U/ml apyrase and subjected to centrifugation at 500 × g for 10 min. Platelets were then subjected to one additional wash with PSG+ PGE 1 /apyrase and then gently resuspended in DMEM at a density of approximately 1×10 8 platelets/100μL. The platelets were then stimulated with thrombin (10 U/ml) or its vehicle (PBS) for 5 minutes and after centrifugation, 0.1% ascorbic acid added to the supernatant to stabilize serotonin. Supernatant serotonin levels were determined using a commercial ELISA (Eagle Biosciences).
Statistics
Comparison of two groups was performed using Student's t-test. Comparison of three or more groups was performed using one-or two-way analysis of variance (ANOVA), as appropriate, and Student-Newman-Keul's post hoc test. The criterion for statistical significance was p ≤ 0.05.
Results

Increased coagulation and platelet accumulation in livers of wild-type mice
Compared to wild-type mice fed control diet, plasma TAT levels were increased in ANITtreated mice, indicating activation of the coagulation cascade (Fig. 1A) . Platelets are the primary cellular source of peripheral serotonin, a mediator shown to exert hepatoprotective effects in liver fibrosis [22, 28] . Plasma levels of serotonin were increased in ANIT-treated mice (Fig. 1B) . Minimal fibrin deposition was observed in wild-type mice fed control diet (Fig. 1C) . In contrast, an increase in peribiliary and sinusoidal fibrin deposits was evident in ANIT-treated mice (Fig. 1C) . Fibrin was also apparent in association with focal areas of hepatocellular necrosis, although these lesions were infrequent in wild-type mice (Fig. 1C) . Scattered α IIB (platelet) staining was confined to sinusoids and larger vessels in mice fed control diet. Hepatic platelet accumulation was evident in livers of ANIT-treated mice (Fig.  1D) . Taken together, the results indicate that ANIT toxicity in mice is associated with activation of the coagulation cascade, hepatic fibrin deposition and platelet accumulation and activation.
Effect of PAR-4 deficiency on serotonin levels, liver injury and biliary hyperplasia in ANITtreated mice
Plasma TAT levels were similar in ANIT-treated wild-type mice (3.8 ± 1.2 ng/ml, n=10) and ANIT-treated PAR-4 −/− mice (3.2 ± 0.5 ng/ml, n=12). Thrombin stimulation has been shown to induce the rapid release of serotonin from human platelets [13] . Consistent with this, we found that thrombin stimulation induced serotonin release from isolated wild-type platelets, and this was significantly reduced in isolated PAR-4 −/− platelets (Supplemental Fig. 1 ). Plasma serotonin levels increased in ANIT-treated wild-type mice, but not in ANITtreated PAR-4 −/− mice ( Fig. 2A) . A previous study suggested that platelet-derived serotonin inhibits cholestatic liver injury, in part through regulation of the bile acid pool [22] . Consistent with this observation, serum bile acids increased significantly in ANIT-treated wild-type mice, and increased further in ANIT-treated PAR-4 −/− mice (Fig. 2B) . Serum ALT and ALP activities increased to a greater extent in ANIT-treated PAR-4 −/− mice compared to ANIT-treated wild-type mice (Fig. 2C-D) . The overall histological appearance of control diet fed WT and PAR4 −/− mice was similar (Fig. 2F ). In agreement with the increase in serum ALT, the number of necrotic lesions was significantly increased in livers of ANIT-treated PAR-4 −/− mice compared to ANIT-treated wild-type mice, although the average size of necrotic foci was unaffected by genotype (Fig. 2E ).
ANIT-treated mice developed biliary hyperplasia, which was not affected by genotype, as indicated by CK19 staining and quantification (Supplemental Fig. 2A-B) . Liver histopathology indicated increased portal inflammation and biliary fibrosis in ANIT-treated wild-type mice (Fig. 2F) , which qualitative assessment suggested was slightly more severe in PAR-4 −/− mice. In agreement with previous studies [26, 29, 30] , we identified portal inflammation in ANIT-treated mice as predominantly a lymphocytic infiltrate. Indeed, accumulation of CD3 + lymphocytes increased in ANIT-treated wild-type mice, and this was exacerbated in ANIT-treated PAR-4 −/− mice (Supplemental Fig. 3A-B) . Consistent with enhanced inflammation, plasma IL-6 levels were significantly increased in ANIT-treated PAR-4 −/− mice, although other cytokines examined were unaffected (Supplemental Fig.  3C ).
Increased liver fibrosis in ANIT-treated PAR-4 −/− mice
Because our analysis of liver histopathology suggested more peribiliary fibrosis in PAR-4 −/− mice, we examined the expression of profibrogenic changes and collagen deposits in ANITtreated mice. Hepatic expression of profibrogenic COL1A1, TGFβ2, ITGB6, and TIMP-1 mRNAs was increased significantly in livers of ANIT-treated wild-type mice compared to control diet fed animals (Fig. 3A) . Induction of each mRNA increased further in ANITtreated PAR-4 −/− mice, although increases in TGFβ1 and TGFβ2 mRNA did not achieve statistical significance (Fig. 3A) . Peribiliary expression of α-SMA, a marker of activated hepatic stellate cells and portal fibroblasts, increased in livers of ANIT-treated wild-type mice (Fig. 3B) , and this increase was larger in livers of ANIT-treated PAR-4 −/− mice (Fig.  3B-C) . Peribiliary collagen deposition, as indicated by sirius red staining (Fig 4A-B) and type 1 collagen immunofluorescence (Fig. 4C-D) , increased in livers of ANIT-treated wildtype mice compared to control diet fed wild-type mice. In agreement with liver histology and profibrogenic gene expression, this was significantly increased in livers of ANIT-treated PAR-4 −/− mice ( Fig. 4B and 4D ).
Increased hepatocellular necrosis and hepatic inflammation in ANIT-treated Fibγ Δ5 mice
Fibγ Δ5 mice express normal levels of a mutant fibrin(ogen) that does not bind to the platelet integrin α IIb β 3 [15] . In contrast to PAR-4 deficiency, plasma serotonin levels were similar in ANIT-treated wild-type and Fibγ Δ5 mice (37 ± 4 ng/ml vs. 41 ± 8 ng/ml, respectively, n=6). However, serum ALT activity and bile acids were significantly higher in ANIT-treated Fibγ Δ5 mice compared to ANIT-treated wild-type mice (Fig. 5A-B) . Serum ALP activity increased in ANIT-treated mice of both genotypes (Fig. 5C ). The overall histological appearance of control diet fed wild-type and Fibγ Δ5 mice was similar (Fig. 5D ). Extensive multifocal acute hepatocellular coagulative necrosis was present in ANIT-treated Fibγ Δ5 mice, and this was minimal in ANIT-treated wild-type mice (Fig. 5D-E) . Although necrotic foci were of similar size in wild-type mice and Fibγ Δ5 mice, the number of necrotic foci and thus, total area of necrosis, were significantly increased in ANIT-treated Fibγ Δ5 mice (Fig.  5F ). Potentially owing to expression of tissue factor by injured hepatocytes [31] , plasma TAT levels were significantly elevated in ANIT-treated Fibγ Δ5 mice (5.8 ± 0.9 ng/ml, n=6) compared to ANIT-treated wild-type mice (3.5 ± 0.25 ng/ml, n=6). Biliary hyperplasia was also exacerbated in ANIT-treated Fibγ Δ5 mice, as indicated by a significant increase in CK19 staining (Supplemental Fig. 2C-D) .
Qualitative assessment of liver histopathology indicated markedly increased portal inflammation in livers of ANIT-treated Fibγ Δ5 mice compared to ANIT-treated wild-type mice ( Fig. 5D-E) . In agreement with this observation, CD3+ lymphocyte accumulation was exacerbated in ANIT-treated Fibγ Δ5 mice compared to ANIT-treated wild-type mice (Fig.  6A-B ). Neutrophils were also commonly associated with necrotic lesions in ANIT-treated Fibγ Δ5 mice (Supplemental Fig. 4 ). In agreement with increased cellular inflammation, plasma levels of IL-6, TNFα, IL-4 and KC/Gro were significantly increased in ANIT-treated Fibγ Δ5 mice (Fig. 6C) .
Increased liver fibrosis in ANIT-treated Fibγ Δ5 mice
Compared to wild-type mice fed control diet, hepatic expression of profibrogenic COL1A1, TGFβ2, ITGβ6, and TIMP-1 mRNAs was increased in livers of ANIT-treated wild-type mice for 4 weeks, and induction of each gene was significantly enhanced in ANIT-treated Fibγ Δ5 mice (Fig. 7A) . Moreover, TGFβ1 mRNA levels increased in livers of ANIT-treated Fibγ Δ5 mice (Fig. 7A) . Compared to ANIT-treated wild-type mice, α-SMA staining was dramatically increased near bile ducts in livers of ANIT-treated Fibγ Δ5 mice (Fig. 7B-C) . Extensive α-SMA staining was evident within and at the periphery of necrotic lesions in ANIT-treated Fibγ Δ5 mice (Fig. 7B ). In agreement with these indicators of a profibrogenic response, hepatic collagen deposition was dramatically increased in livers of ANIT-treated Fibγ Δ5 mice compared to ANIT-treated wild-type mice, as indicated by sirius red staining (Fig. 8A-B) and type 1 collagen immunofluorescence (Fig. 8C-D) .
Discussion
The literature is somewhat perplexing as to the role of platelets in liver disease, and it is challenging to conclude that platelets have a unified role in all forms of liver injury and fibrosis. Differences in the experimental basis of liver damage, subtle changes in the timing, duration and/or extent of thrombocytopenia, and the potency/efficacy of antiplatelet interventions (genetic or pharmacologic) may each impact interpretation of the role of platelets. For example, whereas platelet-derived serotonin is reported to promote liver repair/ regeneration and inhibit liver fibrosis in some systems [22, 28, 32, 33] , its role is reversed in settings of viral hepatitis and non-alcoholic steatohepatitis [34, 35] . Platelets contribute to the acute phase of cholestatic liver injury induced by BDL or a single, large dose of ANIT [19] [20] [21] . Likewise, short term (48 hour) antibody-mediated thrombocytopenia reduced hepatic α-SMA levels in 8-week-old Mdr2 −/− mice [18] . In contrast, prolonged thrombocytopenia exacerbates long-term BDL-induced liver fibrosis, as does a lack of peripheral serotonin [17, 22] . Notably, a similar dichotomy exists for the role of fibrin(ogen). For example, where fibrin(ogen) is deleterious in acute ANIT hepatotoxicity [36] , our findings here in Fibγ Δ5 mice and previously in fibrin(ogen)-null mice [26] suggest that protective properties of fibrin(ogen) emerge as the liver insult becomes chronic. Collectively, these studies highlight the diverse functions of platelets in liver disease, and emphasize a need to obtain a deeper understanding of the context-dependent role of platelets in liver disease.
PAR-1 and α IIB β 3 antagonists represent targets for antiplatelet therapy in humans [37, 38] and similar effects on platelet activation are observed in PAR-4-deficient mice [12] , in α IIB β 3 -deficient mice [39, 40] , and in mice expressing γ Δ5 fibrin(ogen) [15] , which does not support platelet aggregation. Here, we found that PAR-4 deficiency and disruption of fibrin(ogen) engagement of α IIB β 3 increased fibrosis caused by chronic biliary injury. In contrast, a recent study found that aspirin significantly reduced fibrosis in Mdr2 −/− mice, another model of peribiliary fibrosis [18] . By way of comparison, aspirin prolonged bleeding time by 1.4-fold [18] , whereas bleeding times are prolonged by >5-fold in PAR-4 −/− mice and Fibγ Δ5 mice [12, 15] . This suggests that severe defects in platelet function (e.g., lack of thrombin signaling or fibrin(ogen) engagement) can result in increased liver fibrosis, analogous to long-term thrombocytopenia. In contrast, less potent inhibition of platelet activation (e.g., aspirin) may inhibit liver fibrosis, yet preserve protective platelet functions.
Several studies have implicated platelet-derived serotonin as a mediator capable of suppressing cholestatic liver injury and biliary fibrosis [22, 33, 41] . However, the mechanism whereby platelets are stimulated to release serotonin during cholestasis has not been fully characterized. We found that PAR-4 deficiency significantly reduced thrombinmediated serotonin release in isolated mouse platelets, and plasma serotonin did not increase in ANIT-treated PAR-4 −/− mice. This strongly suggests that thrombin-mediated platelet activation is central to serotonin release in cholestasis, although additional studies will be required to elucidate whether changes in serotonin contribute to increased fibrosis in PAR-4 −/− mice. Our results are at least consistent with those in the BDL model, where defective platelet serotonin release is associated with alterations in the bile acid pool, a proposed mechanism whereby liver fibrosis is exacerbated [22] .
Disruption of thrombin signaling and fibrin-α IIB β 3 integrin engagement, in PAR-4 −/− mice and Fibγ Δ5 mice, respectively, increased hepatocyte injury in mice fed ANIT diet, as indicated by serum ALT activity and liver necrosis. However, the severity of hepatocellular necrosis was more dramatic in ANIT-treated Fibγ Δ5 mice, and profibrogenic changes such as fibroblast activation and collagen deposition within necrotic areas suggest incomplete repair of necrosis. Whereas changes in plasma serotonin may account for liver pathology in PAR-4 −/− mice, plasma serotonin levels in ANIT-treated mice were unaffected by fibrin(ogen) mutation. This suggests that the α IIb β 3 integrin-fibrin interaction does not augment platelet serotonin release in this context. In other settings, fibrin(ogen) engagement of integrin α IIB β 3 can facilitate wound repair by promoting platelet aggregation and clot retraction [42, 43] . It is conceivable that in the context of chronic cholestatic liver injury, γ Δ5 fibrin(ogen) fails to support appropriate platelet aggregation and localized release of repair mediators. Additional studies are required to determine whether defective liver repair causes increased liver necrosis in ANIT-treated Fibγ Δ5 mice.
Strong experimental evidence in BDL, carbon tetrachloride and ANIT models indicates that the thrombin receptor PAR-1 contributes to fibrosis in multiple tissues, including the liver [2, 4, 7, 8] . Use of PAR-1 −/− mice does not directly address the role of thrombin-mediated platelet activation in liver fibrosis, because platelets in PAR-1 null mice are fully responsive to thrombin [10] . Likewise, PAR-1 activation of stellate cells and portal fibroblasts would be retained in PAR-4 null mice, despite a lack of thrombin signaling in platelets. The observation that PAR-4 deficiency increased liver fibrosis in a model where PAR-1 deficiency reduces fibrosis suggests dichotomous roles of thrombin in this experimental setting. It would be interesting to observe the combined effect of platelet and non-platelet PAR signaling on liver fibrosis. Possible approaches include use of PAR-1/PAR-4 double deficient mice, although the phenotype of these mice has not been described. Alternatively, PAR-4 −/− mice administered a PAR-1 antagonist could closely resemble the anticipated effect of a PAR-1 antagonist in patients. Similarly, it would be interesting to evaluate the impact of PAR-4 deficiency in mice expressing γ Δ5 fibrin(ogen), a scenario representing major defects in platelet activation and hemostatic function.
Recent clinical evidence suggests that low-molecular weight heparin delays hepatic decompensation in patients with advanced liver cirrhosis, a majority of which had viral hepatitis [44] . It will be exciting to see whether novel FDA-approved oral anticoagulants (e.g., rivaroxaban, apixaban, dabigatran) that limit thrombin proteolytic activity, are similarly applied as coagulation-directed therapies for liver pathologies. If liver disease (either developing or end-stage) does emerge as an indication for these drugs, it is of importance to determine how coagulation-mediated platelet activation (ie., through fibrin(ogen) or PARs) participates in other models of liver fibrosis. This is particularly important as elements of hemostasis gain traction as biomarkers and potential therapeutic targets in liver disease.
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